Key Metrics
CiteScore 

54.2
Eigenfactor 

0.05 - 0.1
Impact Factor 

>= 25
Scite Index 

0.86 5-Year SI

SJR 

Q1Neurology (clinical)

SNIP 

15.32
Recommended pre-submission checks
Powered by 

Topics Covered on The Lancet Neurology
The Lancet Neurology Journal Specifications
| Overview | |
| Publisher | ELSEVIER SCIENCE INC |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 2002 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in The Lancet Neurology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in The Lancet Neurology
Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trial.
- 1 Aug 2026
- The Lancet. Neurology
Diagnosis of exclusion versus no better explanation.
- 1 Aug 2026
- The Lancet. Neurology
Tavapadon for the treatment of Parkinson's disease.
- 1 Aug 2026
- The Lancet. Neurology
Natalia Rost: a happy warrior for brain health.
- 1 Aug 2026
- The Lancet. Neurology
Natural experiments on herpes zoster vaccines and dementia - Author's reply.
- 1 Aug 2026
- The Lancet. Neurology
Epstein-Barr virus and multiple sclerosis: from associations to mechanisms to potential therapies.
- 1 Aug 2026
- The Lancet. Neurology
Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trial.
- 1 Aug 2026
- The Lancet. Neurology
Diagnosis of exclusion versus no better explanation.
- 1 Aug 2026
- The Lancet. Neurology
Tavapadon for the treatment of Parkinson's disease.
- 1 Aug 2026
- The Lancet. Neurology
Natalia Rost: a happy warrior for brain health.
- 1 Aug 2026
- The Lancet. Neurology
Natural experiments on herpes zoster vaccines and dementia - Author's reply.
- 1 Aug 2026
- The Lancet. Neurology
Epstein-Barr virus and multiple sclerosis: from associations to mechanisms to potential therapies.
- 1 Aug 2026
- The Lancet. Neurology